Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: A report of 3 cases

AIDS Reader

Volumn 18, Issue 9, 2008, Pages

  Rawizza, Holly E ^a   Sax, Paul E ^a,b  

^a Women's Hospital   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antiretroviral therapy; Darunavir; Drug resistance; HIV AIDS; Nnrtis; Pharmacokinetics

Indexed keywords

AMPRENAVIR PHOSPHATE; DARUNAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; LAMIVUDINE PLUS STAVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; TENOFOVIR; TIPRANAVIR; VIRUS RNA; PROTEINASE INHIBITOR; SULFONAMIDE;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; ARTICLE; BIPOLAR DISORDER; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENTAL DISEASE; MONOTHERAPY; ADULT; ANTIVIRAL SUSCEPTIBILITY; BIOAVAILABILITY; CASE REPORT; DRUG SUBSTITUTION; FEMALE; GENE MUTATION; GENETIC SCREENING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MINIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANCE; DRUG COMBINATION;

DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; RITONAVIR; SULFONAMIDES;

EID: 53449092718     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Lima V, Hudson E, Wynhoven B, et al. Drastically declining incidence of HIV drug resistance; the end of the beginning? 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston. Abstract 895.
2. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21:395-402.
3. Haubrich R, Berger D, Chiliade P, et al; POWER 2 Study Group. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. 2007;21:F11-F18.
4. Clotet B, Bellos N, Molina JM, et al; POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials [published correction appears in Lancet. 2008;371:116]. Lancet. 2007;369:1169-1178.
5. Madruga JV, Berger D, McMurchie M, et al; TITAN Study Group. Efficacy and safety of darunavir-rito-navir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370:49-58.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008;1-128. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed July 11,2008. Table 12, page 72.
7. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med. 2007;15:119-125.
8. Poveda E, de Mendoza C, Martin-Carbonero L, et al. Prevalence of darunavir resistance mutations in HIV-l-infected patients failing other protease inhibitors. JAntimicrob Chemother. 2007;60:885-888. 9. Cohen CI, Falcon R, Rinehart A, Lefebvre E. Factors influencing darunavir/r efficacy in treatment experienced HIV patients: POWER 1,2, and 3 pooled 48-week analysis. 44th Annual Meeting of the Infectious Diseases Society of America; October 12-15, 2006; Toronto. Abstract P688.
9. De Meyer S, Vangeneugden T, Lefebvre E, et al. Phenotypic and genotypic determinants of TMC114 (darunavir) resistance: POWER 1, 2 and 3 pooled analysis. 8th International Congress on Drug Therapy in HIV Infection; November 12-16,2006; Glasgow, UK. Abstract P196.
10. Scholler M, Kraft M, Hoetelmans R, et al. Significant decrease in TMC125 exposures when coadministered with tipranavir boosted with ritonavir in health subjects. 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver. Abstract 583.
11. Sekar VJ, De Pauw M, Mariën K, et al. Pharmacokinetic interaction between TMCl14/r and efa-virenz in healthy volunteers. Antivir Ther. 2007;12: 509-514.
12. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet. 2001;40:893-905.
13. Mouly S, Lown KS, Komhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther. 2002;72:1-9.
14. Sekar V, Lefebvre E, Mariën K, et al. Pharmacokinetic interaction between the antiretroviral agents TMC114 and nevirapine, in the presence of low-dose ritonavir. 44th Annual Meeting of the Infectious Diseases Society of America; October 12-15,2006; Toronto. Abstract 956.
15. Boffito M, Moyle G, Hill A, et al. The pharmacokinetic (PK) profile of darunavir with low-dose ritonavir (DRV/r) in various multiple-dose regimens over 120 hours. 9th International Workshop on Clinical Pharmacology of HIV Therapy; April 7-9,2008; NewOrleans.www.natap.org/2008/Pharm/Pharm-13.htm.
16. Antinori A, Zaccarelli M, Cingolani A, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses. 2002; 18:835-838.
17. Vingerhoets I, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol. 2005;79:12773-12782.
18. Vingerhoets J, Janssen K, Welkenhuysen-Gybels J, et al. Impact of baseline K103N or Y181C on the virological response to the NNRTITMC125: analysis of study TMC125-C223. Antivir Ther. 2006;11:S22.
19. Vingerhoets J, Buelens A, Peeter 5 M, et al. Impact of baseline mutations NNRTI mutations on the virlogical response to TMC125 in the phase III clinical trials DUET-1 and DUET-2. Antivir Ther. 2007;12:S34.
20. Madruga IV, Cahn P, Grinsztejn B, et al; DUET-1 Study Group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-l-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29-38.
21. Lazzarin A, Campbell T, Clotet B, et al; DUET-2 Study Group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-l-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39-48.
22. Gazzard BG, Pozniak AL, Rosenbaum W, et al. An open-label assessment of TMC125-a new, next- generation NNRTI, for 7 days in H1V-1 infected individuals with NNRTI resistance. AIDS. 2003;17:F49- F54.
23. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004;48:4680-4686.
24. Das K, Clark AD Jr, Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem. 2004;47:2550-2560.
25. Scholler-Gyure M, Kakuda TN, Sekar V, et al. Pharmacokineucs of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Aniivir Ther. 2007;12:789-796.
26. Kakuda TN, Schöller-Gyure M, Peeters M, et al. Pharmacokinetic interaction study with TMC125 and TMC114/r in HIV-negative volunteers. 16th International AIDS Conference; August 13-18, 2006; Toronto. Poster TUPE0086.
27. Vingerhoets J, Peeters M, Corbett C, et al. Effect of baseline resistance on the virologic response to a novel NNRTI, TMC125, in patients with extensive NNRTT and PI resistance: analysis of study TMC125- 223. 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver. Abstract 154.
28. Boffito M, Winston A, Jackson A, et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS. 2007;21:1449- 1455.
29. Intelence (etravirine) [package insert]. Raritan, NJ: Tibotec Therapeutics Inc; January 2008.
30. Kakuda T, Wade J, Snoeck E, et al. Pharmacokinetics and pharmacodynamics of the NNRTI TMC125 in treatment-experienced HIV-l-infected patients: pooled 24-week results of DUET-1 and DUET-2.15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston. Abstract 762.
31. Cooper D, Gatell J, Rockstroh J, et al. 48-Week results from BENCHMRK-1, a phase III study of raltegravir in patients failing ART with triple-class resistant HIV-1.15th Conference on Retroviruses and Opportunistic Infections; February 3-6,2008; Boston. Abstract 788.
32. Hardy D, Reynes J, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6,2008; Boston. Abstract 792.